Status:
UNKNOWN
Immunohistochemical Assessment of Programmed Death ligand1 and LC3B in GBM
Lead Sponsor:
Assiut University
Conditions:
Glioblastoma Multiforme
Eligibility:
All Genders
18-70 years
Brief Summary
Glioblastoma(GBM) is the most common malignant primary brain tumor and has unfortunately bad prognosis .PDL(Programmed death lignad 1)1 is alignad for a protein receptor PD1(Programmed death 1) that u...
Detailed Description
Gliomas account for almost 30% of all primary brain tumours, and are responsible for the majority of deaths from primary brain tumours . Glioblastoma is the most common primary malignant brain tumor ...
Eligibility Criteria
Inclusion
- \- Glioblastoma Multiforme patients with available follow up data
Exclusion
- Specimens with no available follow up data
Key Trial Info
Start Date :
March 1 2020
Trial Type :
OBSERVATIONAL
Allocation :
ESTIMATED
End Date :
September 1 2022
Estimated Enrollment :
61 Patients enrolled
Trial Details
Trial ID
NCT04284306
Start Date
March 1 2020
End Date
September 1 2022
Last Update
February 25 2020
Active Locations (0)
Enter a location and click search to find clinical trials sorted by distance.
No Results Found
We couldn’t find results for the location/zipcode entered or within the selected range. Please check your input or adjust your search.